Showing results (11-20 of 43) with videos related to
Sort By:
Pageof 5
Psychopharmacology|August 6, 1999
Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteersD Y Lee, K U Lee, J S Kwon, et al.Alimentary Pharmacology & Therapeutics|May 26, 2017
A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteersS Yi, H Lee, S B Jang, et al.Clinical Pharmacology and Therapeutics|December 1, 1993
Decreased acetylation of isoniazid in chronic renal failureY G Kim, J G Shin, S G Shin, et al.Alimentary Pharmacology & Therapeutics|June 5, 2018
Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjectsJ Sunwoo, J Oh, S J Moon, et al.Clinical Pharmacology and Therapeutics|September 15, 2001
Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycinK S Yu, J Y Cho, J H Shon, et al.Journal of Korean Medical Science|December 1, 1994
CYP1A2 activity as a risk factor for bladder cancerS W Lee, I J Jang, S G Shin, et al.British Journal of Clinical Pharmacology|November 1, 1996
Erythrocyte thiopurine methyltransferase activity in a Korean populationI J Jang, S G Shin, K H Lee, et al.Clinical Pharmacology and Therapeutics|August 10, 2007
Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjectsJ-Y Chung, J-Y Cho, K-S Yu, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 1, 1997
Temporal changes and reversibility of carbamylated hemoglobin in renal failureJ S Han, Y S Kim, H J Chin, et al.Journal of Clinical Pharmacy and Therapeutics|January 7, 2011
Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokineticsH W Lee, M-s Lim, J Lee, et al.Pageof 5